S&P 500   4,027.81
DOW   32,717.60
QQQ   312.72
3 Undervalued Dividend Payers For Volatile Market Conditions
Adam Mesh: “This Strategy Saved My Trading Career” (Ad)pixel
3 More Downgrades To Put On Your Buy List 
Three Pullback Opportunities in Tech Right Now
Adam Mesh: “This Strategy Saved My Trading Career” (Ad)pixel
Three Mid Caps Wall Street Sees Doubling Within 12 Months
The Most Important Warren Buffett Stock for Investors: His Own
The gold catalyst we’ve waited for (Ad)
Dave & Buster’s Rebound Could Score for Investors 
Micron Technology Goes on Breakout Watch
S&P 500   4,027.81
DOW   32,717.60
QQQ   312.72
3 Undervalued Dividend Payers For Volatile Market Conditions
Adam Mesh: “This Strategy Saved My Trading Career” (Ad)pixel
3 More Downgrades To Put On Your Buy List 
Three Pullback Opportunities in Tech Right Now
Adam Mesh: “This Strategy Saved My Trading Career” (Ad)pixel
Three Mid Caps Wall Street Sees Doubling Within 12 Months
The Most Important Warren Buffett Stock for Investors: His Own
The gold catalyst we’ve waited for (Ad)
Dave & Buster’s Rebound Could Score for Investors 
Micron Technology Goes on Breakout Watch
S&P 500   4,027.81
DOW   32,717.60
QQQ   312.72
3 Undervalued Dividend Payers For Volatile Market Conditions
Adam Mesh: “This Strategy Saved My Trading Career” (Ad)pixel
3 More Downgrades To Put On Your Buy List 
Three Pullback Opportunities in Tech Right Now
Adam Mesh: “This Strategy Saved My Trading Career” (Ad)pixel
Three Mid Caps Wall Street Sees Doubling Within 12 Months
The Most Important Warren Buffett Stock for Investors: His Own
The gold catalyst we’ve waited for (Ad)
Dave & Buster’s Rebound Could Score for Investors 
Micron Technology Goes on Breakout Watch
S&P 500   4,027.81
DOW   32,717.60
QQQ   312.72
3 Undervalued Dividend Payers For Volatile Market Conditions
Adam Mesh: “This Strategy Saved My Trading Career” (Ad)pixel
3 More Downgrades To Put On Your Buy List 
Three Pullback Opportunities in Tech Right Now
Adam Mesh: “This Strategy Saved My Trading Career” (Ad)pixel
Three Mid Caps Wall Street Sees Doubling Within 12 Months
The Most Important Warren Buffett Stock for Investors: His Own
The gold catalyst we’ve waited for (Ad)
Dave & Buster’s Rebound Could Score for Investors 
Micron Technology Goes on Breakout Watch

Kiniksa Pharmaceuticals - KNSA Competitors

$11.15
+0.21 (+1.92%)
(As of 03/29/2023 12:00 AM ET)
Add
Compare
Today's Range
$11.01
$11.27
50-Day Range
$10.94
$14.52
52-Week Range
$7.36
$17.19
Volume
273,826 shs
Average Volume
382,792 shs
Market Capitalization
$777.75 million
P/E Ratio
4.31
Dividend Yield
N/A
Price Target
$20.00

KNSA vs. INVA, PNT, MRUS, PRTC, COLL, BLTE, COGT, ENTA, KURA, and MCRB

Should you be buying Kiniksa Pharmaceuticals stock or one of its competitors? The main competitors of Kiniksa Pharmaceuticals include Innoviva (INVA), POINT Biopharma Global (PNT), Merus (MRUS), PureTech Health (PRTC), Collegium Pharmaceutical (COLL), Belite Bio (BLTE), Cogent Biosciences (COGT), Enanta Pharmaceuticals (ENTA), Kura Oncology (KURA), and Seres Therapeutics (MCRB). These companies are all part of the "pharmaceutical preparations" industry.

Kiniksa Pharmaceuticals vs.

Innoviva (NASDAQ:INVA) and Kiniksa Pharmaceuticals (NASDAQ:KNSA) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their community ranking, media sentiment, profitability, dividends, risk, earnings, institutional ownership, analyst recommendations and valuation.

Innoviva has higher revenue and earnings than Kiniksa Pharmaceuticals. Kiniksa Pharmaceuticals is trading at a lower price-to-earnings ratio than Innoviva, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Innoviva$331.34 million2.35$213.92 million$2.075.39
Kiniksa Pharmaceuticals$220.18 million3.53$183.36 million$2.594.31

In the previous week, Kiniksa Pharmaceuticals had 1 more articles in the media than Innoviva. MarketBeat recorded 3 mentions for Kiniksa Pharmaceuticals and 2 mentions for Innoviva. Kiniksa Pharmaceuticals' average media sentiment score of 1.60 beat Innoviva's score of 0.81 indicating that Kiniksa Pharmaceuticals is being referred to more favorably in the news media.

Company Overall Sentiment
Innoviva Positive
Kiniksa Pharmaceuticals Very Positive

43.0% of Kiniksa Pharmaceuticals shares are held by institutional investors. 0.9% of Innoviva shares are held by company insiders. Comparatively, 54.6% of Kiniksa Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Innoviva received 133 more outperform votes than Kiniksa Pharmaceuticals when rated by MarketBeat users. However, 63.71% of users gave Kiniksa Pharmaceuticals an outperform vote while only 57.74% of users gave Innoviva an outperform vote.

CompanyUnderperformOutperform
InnovivaOutperform Votes
291
57.74%
Underperform Votes
213
42.26%
Kiniksa PharmaceuticalsOutperform Votes
158
63.71%
Underperform Votes
90
36.29%

Kiniksa Pharmaceuticals has a net margin of 83.28% compared to Innoviva's net margin of 64.56%. Innoviva's return on equity of 18.81% beat Kiniksa Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Innoviva 64.56% 18.81% 9.10%
Kiniksa Pharmaceuticals 83.28% 2.18% 1.76%

Innoviva presently has a consensus price target of $15.17, suggesting a potential upside of 36.02%. Kiniksa Pharmaceuticals has a consensus price target of $20.00, suggesting a potential upside of 79.37%. Given Kiniksa Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Kiniksa Pharmaceuticals is more favorable than Innoviva.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Innoviva
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Kiniksa Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

Innoviva has a beta of 0.56, meaning that its share price is 44% less volatile than the S&P 500. Comparatively, Kiniksa Pharmaceuticals has a beta of -0.07, meaning that its share price is 107% less volatile than the S&P 500.

Summary

Kiniksa Pharmaceuticals beats Innoviva on 10 of the 17 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding KNSA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

KNSA vs. The Competition

MetricKiniksa PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$777.71M$5.62B$4.39B$5.92B
Dividend YieldN/A2.61%2.32%4.51%
P/E Ratio4.3110.42156.4015.78
Price / Sales3.53312.663,519.6862.18
Price / Cash4.2817.9619.9722.47
Price / Book1.964.284.575.11
Net Income$183.36M$187.62M$115.40M$191.64M
7 Day Performance-0.71%1.59%1.58%1.62%
1 Month Performance-13.30%-8.13%-6.50%-5.38%
1 Year Performance11.28%-9.89%-14.96%-17.41%

Kiniksa Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
INVA
Innoviva
2.0015 of 5 stars
$11.15
-1.1%
$15.17
+36.0%
-43.4%$778.05M$331.34M5.395Short Interest ↑
PNT
POINT Biopharma Global
1.8559 of 5 stars
$7.22
+6.5%
$16.25
+125.1%
-11.2%$751.10MN/A-8.3072Earnings Report
Analyst Revision
News Coverage
MRUS
Merus
1.7437 of 5 stars
$17.40
-0.9%
$38.00
+118.4%
-35.0%$805.97M$41.59M-6.00117
PRTC
PureTech Health
1.7126 of 5 stars
$28.99
+6.2%
$55.00
+89.7%
+7.9%$807.37M$17.39M0.00250Short Interest ↑
Gap Up
COLL
Collegium Pharmaceutical
2.2752 of 5 stars
$24.00
-0.7%
$35.00
+45.8%
+18.9%$817.68M$463.93M-32.43152Positive News
BLTE
Belite Bio
2.5821 of 5 stars
$29.54
+1.9%
$57.50
+94.7%
N/A$735.55MN/A0.0012Gap Down
COGT
Cogent Biosciences
1.7792 of 5 stars
$10.43
+3.6%
$22.00
+110.9%
+35.8%$729.58M$7.87M-4.2677Analyst Report
Analyst Revision
News Coverage
ENTA
Enanta Pharmaceuticals
2.3191 of 5 stars
$40.27
+3.7%
$68.60
+70.4%
-42.6%$841.24M$86.16M-6.92155Short Interest ↑
KURA
Kura Oncology
1.9925 of 5 stars
$12.31
-0.3%
$31.20
+153.5%
-26.8%$842.50MN/A-6.06121
MCRB
Seres Therapeutics
1.9835 of 5 stars
$5.62
+1.3%
$16.25
+189.1%
-24.8%$708.57M$7.13M-2.40333Short Interest ↑
This page (NASDAQ:KNSA) was last updated on 3/30/2023 by MarketBeat.com Staff